LightOx Ltd
PrivateLast Round
Grant
Aug 1, 2024
Total Funding Raised
$3.96M
Momentum Score
50 /100
Company Overview
LightOx Ltd is a drug discovery company developing a new class of light-activated chemotherapy for the treatment of early-stage oral cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LightOx Ltd Comps
Public and private peers based on sector, stage, and business model.
LightOx Ltd Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 1, 2024 | ||||
| Series A | Jun 13, 2024 | ||||
| Grant | Jun 6, 2023 | ||||
| Seed | Oct 12, 2021 |
LightOx Ltd Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Meneldor | Seed |
| Northstar Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 138% MoM.
- Apr 24, 2026
Grew 19% QoQ, from 16 to 19 employees.
LightOx Ltd Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about LightOx Ltd's valuation, stock price, and market status.